Researchers working on an incurable blood cancer can now use a new lab model which could make testing potential new ...

Scientists at St. Jude Children's Research Hospital have reconciled two closely related but contentious mechanisms underlying ...

A dual-target CAR T-cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer. Tumors became smaller after the experimental CAR T-cell ...

Glioblastoma is notoriously difficult to treat, largely due to the cancer cell's ability to divide uncontrollably and the protective blood-brain barrier that limits the effectiveness of therapies.

When we hear sounds, specialized cells in the cochlear nucleus are the first to process that information, enabling our brains to understand speech, enjoy music and recognize various noises. For ...

Researchers used lab-grown organoids created from tumors of individuals with glioblastoma (GBM) to accurately model a patient's response to CAR T cell therapy in real time. The organoid's response ...

Eleven months later, CMS said to expect sickle cell disease to be one of the first priorities of the model before later expanding to other conditions. That plan was reemphasized Dec. 4.

This submission supports independent results in an animal model of Glioblastoma Multiforme (GBM), recently published by Mukthavaram et al. (Bioelectron Med 2024 Vol. 10 Issue 1 Pages 10), which ...

Natural killer (NK) cells engineered to express interleukin-21 (IL-21) demonstrated sustained antitumor activity against glioblastoma stem cell-like cells (GSCs) both in vitro and in vivo ...

The team also developed a CAR T cell therapy to target the signaling pathway in the brain through inhibition of ROBO1, the protein that helps guide certain cells, similar to a GPS.

In June a notice posted on the website of the journal Nature set a new scientific record. It withdrew what is now the most highly cited research paper ever to be retracted. The study, published in ...